Chronic GVHD complicated with XXXX and @entity296 after myeloablative hematopoietic stem cell transplantation.

@entity1 @entity296 @entity121 @entity417 @entity882 @entity5442 @entity786 @entity3052 @entity591 @entity2845 @entity281 @entity1778 @entity6558 @entity7129 @entity925 @entity221 @entity491 @entity617 @entity1533
A 50-year-old @entity1 presented with @entity491 , @entity417 , and @entity882 in June 2013. She was diagnosed with de novo @entity3052 with the t(16;21)(q24;q22) translocation. She received an allogeneic hematopoietic stem cell transplant from an @entity1533 locus-mismatched unrelated donor in June 2014. The myeloablative preparative regimen consisted of @entity786 at 60 mg/kg for 2 days and total body irradiation at 12 Gy. On Day 55, she was treated with @entity617 at 20 mg/day for acute GVHD (Grade III; Skin Stage 2, Gut Stage 2, Liver Stage 0) and gradually improved. She had @entity221 , @entity925 in the upper limbs, and asymptomatic @entity7129 on Day 145. Laboratory tests showed elevated CK, CKMB, aldolase, and troponin I. Electromyographic examination revealed @entity121 compatible with the diagnosis of @entity5442 . Electrocardiography showed @entity591 and anteroseptal ST elevation, and echocardiography showed @entity2845 of the left interventricular septal wall without evidence of @entity281 or @entity1778 relapse. She was immediately treated with 40 mg/day @entity617 after the diagnosis of @entity6558 and @entity296 , associated with chronic GVHD. The @entity6558 and @entity296 improved promptly after the administration of @entity617 and the @entity1 remains in remission with a current maintenance program of @entity617 at 5 mg/day.
